Biovie (BIVI) Other Non-Current Liabilities (2017 - 2024)
Biovie (BIVI) posted Other Non-Current Liabilities of $7290.0 for Q4 2024, up 481.34% sequentially from $1254.0 in Q3 2024, and up 11.33% YoY from $6548.0 in Q1 2024.
Biovie (BIVI) Other Non-Current Liabilities (2017 - 2024) Analysis & Trends
Biovie has reported Other Non-Current Liabilities for 7 years, with the latest figure at $7290.0 in Q4 2024.
- Quarterly Other Non-Current Liabilities rose 11.33% year-over-year to $7290.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7290.0 (up 11.33% YoY) and the FY2024 annual result came in at $3771.0, down 99.58% from the prior year.
- Other Non-Current Liabilities advanced to $7290.0 in Q4 2024 per BIVI's latest filing, from $1254.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $16.4 million in Q2 2020 and troughed at $1254.0 in Q3 2024.
- A 5-year average of $1.8 million and a median of $486848.5 in 2021 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities soared 375.6% in 2023, then tumbled 99.74% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $16.4 million in 2020, then slumped by 92.58% to $1.2 million in 2021, then jumped by 51.31% to $1.8 million in 2022, then slumped by 99.64% to $6548.0 in 2023, then rose by 11.33% to $7290.0 in 2024.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $7290.0, $1254.0, and $3771.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7,290.00 |
| Sep 30, 2024 | 1,254.00 |
| Jun 30, 2024 | 3,771.00 |
| Mar 31, 2024 | 48,000.00 |
| Dec 31, 2023 | 6,548.00 |
| Sep 30, 2023 | 489,843.00 |
| Jun 30, 2023 | 894,280.00 |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 442,592.00 |
| Jun 30, 2022 | 188,030.00 |
| Mar 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 1.22 Mn |
| Sep 30, 2021 | 483,854.00 |
| Jun 30, 2020 | 16.41 Mn |
| Mar 31, 2020 | 2.88 Mn |
| Dec 31, 2019 | 2.67 Mn |
| Sep 30, 2019 | 2.53 Mn |
| Mar 31, 2017 | 575,917.00 |